← All Posts
SLS
SELLAS Life Sciences Group, Inc.
June 17, 2026
•
Author: Phil Ratcliff
•
SLS
| Item |
Proposal |
Vote |
| 1 |
The election of two (2) Class I directors to serve on our Board for a three-year term expiring on the date of the 2029 annual meeting of stockholders. |
|
| 1a |
Robert Van Nostrand |
✓ For(116.255)
|
| 1b |
Jane Wasman |
✓ For(116.255)
|
| 2 |
The ratification of the appointment by our Audit Committee of Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. |
✓ For(116.255)
|
| 3 |
To approve an amendment to the Company’s 2023 Amended and Restated Equity Incentive Plan (the “2023 Equity Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2023 Equity Plan by 20,000,000 shares. |
✓ For(116.255)
|
| 4 |
The advisory approval of the compensation of our named executive officers. |
✓ For(116.255)
|
| 5 |
The approval of any postponement or adjournment of the 2026 Annual Meeting, from time to time, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the 2026 Annual Meeting to adopt the proposals set forth above or to establish a quorum. |
✓ For(116.255)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial